Subsequent analysis of subgroups of patients with different clinical variables in the TCGA cohort showed that ESRP1 and RBM5 parts showed prognostic differences, but this does not mean that the results are biased, which may be due to data bias, population susceptibility and cancer heterogeneity. This evidence concerns the gene RBM5 and cancer.